Complete Response with Immunotherapy Alone after Discontinuing VEGF Inhibitor in Advanced Hepatocellular Carcinoma: A Case Report
Open Access
- 27 December 2024
- journal article
- case report
- Published by Jaypee Brothers Medical Publishing in Euroasian Journal of Hepato-Gastroenterology
- Vol. 14 (2) , 246-250
Abstract
Naviwala MSS, Shoaib D, Khan WA, et al. Complete Response with Immunotherapy Alone after Discontinuing VEGF Inhibitor in Advanced Hepatocellular Carcinoma: A Case Report. Euroasian J Hepato-Gastroenterol 2024;14(2):246–250.Keywords
This publication has 24 references indexed in Scilit:
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaNature Communications, 2016
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- New drug toxicities in the onco-nephrology worldKidney International, 2015
- Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patientsWorld Journal of Gastroenterology, 2012
- Bevacizumab Increases Risk for Severe Proteinuria in Cancer PatientsJournal of the American Society of Nephrology, 2010
- VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and managementEuropean Journal of Cancer, 2010
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008
- Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal CancerThe Oncologist, 2007
- Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinomaThe Lancet Oncology, 2007
- Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-AnalysisAmerican Journal of Kidney Diseases, 2007